RxDoctor Payments Data

Megan McGuire

Acute Care · Greenville, SCNPI 1366097230

Payments from drug & device makers

$553in general payments, 2019–2025

Across 25 payments — averaging $22.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$150
  • Novo Nordisk$47
  • Pfizer$43
  • Novartis$35
  • Amgen$31
  • E.r. Squibb & Sons, L.L.C.$28
  • plus $218 from 12 others

What the payments were for

  • Food & beverage$553100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$553 in reported general payments places this provider in the 50th percentile of 339 acute care providers in South Carolina.

See all acute care providers in South Carolina

Medicare billing

Part B allowed, 2024
$60,353
Medicare patients
418
Services billed
711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban752$761,989
XareltoRivaroxaban177$154,542
Flecainide Acetate347$13,866
Metoprolol Succinate446$6,499
Mexiletine Hcl31$3,676
Amiodarone Hcl154$3,356
Dabigatran EtexilateDabigatran Etexilate Mesylate11$3,279
Dofetilide21$2,142
SotalolSotalol Hcl92$1,997
Diltiazem 24hr Er (Cd)Diltiazem Hcl65$1,594
Propafenone Hcl28$1,399
Metoprolol Tartrate93$757
Potassium Chloride14$352
Carvedilol30$241
Warfarin Sodium20$195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$43$761,989752 claims
Johnson & JohnsonXarelto$17$154,542177 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 339 acute care providers in South Carolina.

Other acute care in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →